Recent articles for private investors with a focus on dividend announcements
Millennium & Copthorne reduces their 2015 full year dividend by 52.8%
Group RevPAR for 2015 increased by 0.6% to £71.98 (2014: £71.55). In constant currency, RevPAR decreased by 1.3%. For the fourth quarter of 2015, RevPAR in constant currency fell by 4.1%.
Fidessa increases its 2015 full year dividend by 2%
Highlights for the period ended 31st December 2015:
Acacia Mining maintains its 2015 full year dividend at last years level
Acacia Mining plc (“Acacia’’) reports full year 2015 results
Randgold increases its 2015 full year dividend by 10%
Randgold Resources chief executive Mark Bristow today described 2015 as one of the best years in the company's history as it faced down the challenges surrounding the embattled gold mining industry to post performance improvements and advances on every front
Beazley increases its 2015 full year dividend by 6.45% and pays special
Beazley plc results for year ended 31st December 2015
GlaxoSmithkline 2015 full year results
Summary
·
Group sales +6% CER on a reported basis and +1% CER pro-forma
-
Pharmaceuticals £14.2 billion, -7% (-1% pro-forma); Vaccines £3.7 billion, +19% (+3% pro-forma); Consumer Healthcare £6 billion, +44% (+6% pro-forma)
·
£2 billion of new product sales driven by HIV (Tivicay, Triumeq), Respiratory (Relvar/Breo, Anoro,Incruse) and Meningitis vaccines (Menveo, Bexsero)
-
Growing sales contribution: Q4 sales £682 million, (Q3: £591 million)
-
Nucala, a new biologic treatment for severe asthma, launched at the end of 2015
-
New product sales now expected to reach £6 billion target up to two years earlier (2018 vs 2020)
·
Integration and restructuring programme on schedule
-
£1 billion incremental annual cost savings delivered in 2015 for costs of £1.9 billion
-
On track to deliver £3 billion of annual cost savings by end 2017
·
2015 core EPS 75.7p, -15% CER, ahead of financial guidance
-
Reflects short-term dilution from transaction partly offset by integration and restructuring benefits
·
2015 total EPS 174.3p, +>100% CER
-
Reflects impact of transaction gains, partly offset by restructuring charges and revaluation of the contingent consideration relating to improved outlook for HIV business
·
2016 core EPS percentage growth expected to reach double digits CER
-
If FX rates held at January average levels estimated impact of +5% on 2016 Sterling core EPS growth
·
2015 ordinary dividend of 80p and special dividend of 20p confirmed
-
Special dividend to be paid alongside Q4 ordinary dividend in April 2016
-
Continue to expect 80p full year dividend for 2016 and 2017
·
New R&D portfolio of ~40 assets to drive long-term performance; multiple development milestones expected in 2016/2017
-
Up to 10 regulatory filings include Shingrix (shingles vaccine), sirukumab (RA), Benlysta SC (lupus) and ICS/LABA/LAMA (COPD)
-
Up to 10 Phase lll starts include cabotegravir (HIV), daprodustat (anaemia) and Men ABCWY vaccine
-
Up to 20 Phase ll starts in Immuno-inflammation, Oncology, Respiratory and Infectious diseases
-
Estimated R&D rate of return maintained at 13%
Low & Bonar increases its 2015 full year dividend by 3%
Good progress made in all global business units; Civil Engineering stabilised
Entu declares 2.67p final dividend in line with guidance
Final Results for the Year Ended 31 October 2015
4451-4500 of 7561
